Get the Stockscreener App
9.96
4.18%
0.40
After Hours:
10.10
0.14
+1.41%
Candel Therapeutics Inc stock is traded at $9.96, with a volume of 1.27M.
It is up +4.18% in the last 24 hours and up +1.74% over the past month.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$9.56
Open:
$9.51
24h Volume:
1.27M
Relative Volume:
0.65
Market Cap:
$729.77M
Revenue:
$31,000
Net Income/Loss:
$-54.42M
P/E Ratio:
-10.19
EPS:
-0.9778
Net Cash Flow:
$-48.99M
1W Performance:
+4.08%
1M Performance:
+1.74%
6M Performance:
+63.28%
1Y Performance:
+41.88%
1-Day Range:
$9.51
$10.20
1-Week Range:
$9.455
$10.30
52-Week Range:
$4.35
$11.36
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
9.96 | 700.46M | 31,000 | -54.42M | -48.99M | -0.9778 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-28-25 | Initiated | Stephens | Overweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-30-25 | Resumed | H.C. Wainwright | Buy |
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Candel Therapeutics Inc (CADL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BlackRock (CADL holder) discloses 6.6% Candel Therapeutics stake on Schedule 13G - Stock Titan
CADL|Candel Therapeutics Inc|Price:9.560|Chg%:-0.300 - TradingKey
Candel Therapeutics Inc (CADL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Candel Therapeutics Inc (CADL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally? - Stocktwits
TradingKey - TradingKey
Candel Therapeutics Inc (CADL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ETFs Investing in Candel Therapeutics, Inc. Stocks - TradingView
Candel Therapeutics Insider Ups Holding By 14% During Year - simplywall.st
Candel Therapeutics (NASDAQ:CADL) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Candel Therapeutics Reported Better-Than-Feared Q1 Loss – But All Eyes Turn To This Pivotal Event Tomorrow - Stocktwits
Candel Therapeutics (NASDAQ:CADL) Shares Up 8.1%Here's Why - MarketBeat
CADL Stock Edges Up After Hours On Strong Extended Prostate Cancer Data - Stocktwits
Why CADL Stock Plunged Nearly 15% In After-Hours Trading Today - Stocktwits
Stifel Initiates Candel Therapeutics(CADL.US) With Buy Rating, Announces Target Price $22 - Moomoo
Liquidity Mapping Around (CADL) Price Events - Stock Traders Daily
CADL Initiates Coverage On Candel Therapeutics by Stifel -- Buy Rating Issued - GuruFocus
CADL Q1 2026 Earnings: Narrower Loss Per Share Surpasses Analyst Estimates Amid Ongoing Pipeline DevelopmentDebt Analysis Report - Bölüm Sonu Canavarı
Stifel initiates Candel Therapeutics stock with buy, $22 target By Investing.com - Investing.com Australia
Stifel initiates Candel Therapeutics stock with buy, $22 target - Investing.com UK
Candel Therapeutics (CADL) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)July 8, 2026 - marketscreener.com
Form 4 Candel Therapeutics Inc For: 8 July By Investing.com - Investing.com Nigeria
[Form 4] Candel Therapeutics, Inc. Insider Trading Activity - Stock Titan
Candel Therapeutics (CADL) Chief Commercial Officer Sims listed in Form 3 - Stock Titan
Candel hands its new commercial chief 285,000 options - Stock Titan
Candel Therapeutics: An Overlooked Late-Stage Biotech With Real Potential - Seeking Alpha
Candel Therapeutics Q1 2026 Earnings: EPS Beats Estimates by 56.68% as Clinical Development AdvancesMargin Expansion Trends - dars.gov.et
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail
Why (CADL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Insider Sell: Francesca Barone Sells Shares of Candel Therapeuti - GuruFocus
Candel Therapeutics CSO Francesca Barone sells $235k in stock By Investing.com - Investing.com Australia
Candel Therapeutics CSO Francesca Barone sells $235k in stock - Investing.com
Form 4 Candel Therapeutics Inc For: 1 July By Investing.com - Investing.com UK
Candel Therapeutics (CADL) CSO executes 23,447-share open-market sale under 10b5-1 plan - Stock Titan
Candel Therapeutics (CADL) CTO sells 7,000 shares in planned trade - Stock Titan
Candel Therapeutics (CADL) director receives fully vested grant of 2,199 stock options - Stock Titan
Candel Therapeutics (CADL) director receives fully vested option award - Stock Titan
Candel Therapeutics (CADL) director receives fully vested 381-option equity grant - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):